Chemistry:Naphthylpropylaminopentane
 | |
 | |
| Clinical data | |
|---|---|
| Other names | 1-(2-Naphthyl)-2-propylaminopentane; NPAP; 2-Naphthyl-α,N-dipropylphenethylamine |
| Drug class | Monoaminergic activity enhancer |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C18H25N |
| Molar mass | 255.405 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
1-(2-Naphthyl)-2-propylaminopentane (NPAP), also known as 2-naphthyl-α,N-dipropylphenethylamine, is a monoaminergic activity enhancer (MAE) of the α-propylphenethylamine and naphthylaminopropane families related to phenylpropylaminopentane (PPAP).[1] It is the analogue of PPAP in which the phenyl ring has been replaced with a naphthalene ring.[1] MAEs are agents that enhance the action potential-mediated release of monoamine neurotransmitters.[2][3][4] NPAP is a MAE of norepinephrine and dopamine but not of serotonin.[1] Its potency is similar to that of PPAP.[1] As with PPAP, the (–)-enantiomer of NPAP is more potent as a MAE.[1] Like PPAP, it is inactive as a classical monoamine releasing agent.[1] NPAP was developed by József Knoll and colleagues and was first described in 2001.[1]
See also
- Substituted naphthylethylamine
- Substituted α-propylphenethylamine
- Methylenedioxyphenylpropylaminopentane (MPAP)
- Benzofuranylpropylaminopentane (BPAP)
- Indolylpropylaminopentane (IPAP)
- Naphthylaminopropane
- Ethylnaphthylaminopropane
- Naphyrone (naphthylpyrovalerone)
- Ethylnaphthidate (HDEP-28)
- Methylnaphthidate (HDMP-28)
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain". Bioorganic & Medicinal Chemistry 9 (5): 1197–1212. May 2001. doi:10.1016/s0968-0896(01)00002-5. PMID 11377178.
- ↑ "Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives". Progress in Neuro-Psychopharmacology & Biological Psychiatry 28 (3): 421–427. May 2004. doi:10.1016/j.pnpbp.2003.11.016. PMID 15093948.
- ↑ "The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015)". Molecular Psychiatry 21 (11): 1499–1503. November 2016. doi:10.1038/mp.2016.127. PMID 27480491.
- ↑ "Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives". Neurochemical Research 28 (8): 1275–1297. August 2003. doi:10.1023/a:1024224311289. PMID 12834268.
Template:Monoaminergic activity enhancers
 |  |
